---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（20193911451811.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文艾力雅处方资料（仅供参考）

【英文名称】Eylea

【适用证】

Eylea是一种注射到眼睛中的溶液，用于治疗成人的眼部疾病

- 新生血管性（湿性）年龄相关性黄斑变性（湿性AMD），

- 由视网膜静脉阻塞继发黄斑水肿引起的视力受损（分支RVO（BRVO）或中央RVO（CRVO）），

- 糖尿病性黄斑水肿（DME）引起的视力受损，

- 由于近视脉络膜新生血管形成（近视CNV）引起的视力受损。

阿立哌啶（Eylea中的活性物质）阻断一组因子的活性，称为血管内皮生长因子A（VEGF-A）和胎盘生长因子（PlGF）。

在患有湿性AMD和近视CNV的患者中，这些过量的因素涉及眼睛中新血管的异常形成。这些新血管可导致血液成分泄漏到眼睛中，并最终损害负责视力的眼睛组织

在患有CRVO的患者中，主血管中发生阻塞，血液将血液从视网膜传输出去。 VEGF水平响应升高，导致流体渗漏到视网膜中，从而导致黄斑肿胀（视网膜的部分负责精细视力），这被称为黄斑水肿。当黄斑充满液体时，中央视力变得模糊。

在患有BRVO的患者中，阻断了将血液从视网膜传输出去的主血管的一个或多个分支。 VEGF水平响应升高，导致流体渗漏到视网膜中，从而引起黄斑水肿。

糖尿病性黄斑水肿是由于黄斑内血管中的液体泄漏而在糖尿病患者中发生的视网膜肿胀。黄斑是视网膜的一部分，负责精细视力。当黄斑充满液体时，中央视力变得模糊。

已经证明，Eylea可以阻止眼睛中新的异常血管的生长，这些血管经常会漏液或出血。 Eylea可以帮助稳定，并且在许多情况下，可以改善与湿性AMD，CRVO，BRVO，DME和近视CNV相关的视力丧失。

【用法用量】

经验丰富的医生会在无菌（清洁和无菌）条件下将Eylea注入您的眼睛。

推荐剂量为2 mg aflibercept（50微升）。

将Eylea注射到眼睛中（玻璃体内注射）。

在注射之前，医生会使用消毒液清洗眼睛，以防止感染。 您的医生也会给您局部麻醉剂，以减少或预防您注射时可能出现的任何疼痛。

【注意事项】

你不会得到Eylea：

- 如果您对阿柏西普或该药物的任何其他成分过敏。

- 如果您眼内或周围有活动性或疑似感染（眼部或眼周感染）。

- 如果您有严重的眼部炎症（表现为疼痛或发红）。

【What Eylea is and what it is used for】

Eylea is a solution which is injected into the eye to treat eye conditions in adults called

- neovascular (wet) age-related macular degeneration (wet AMD),

- impaired vision due to macular oedema secondary to retinal vein occlusion (branch RVO (BRVO) or central RVO (CRVO)),

- impaired vision due to diabetic macular oedema (DME),

- impaired vision due to myopic choroidal neovascularisation (myopic CNV).

Aflibercept, the active substance in Eylea, blocks the activity of a group of factors, known as Vascular Endothelial Growth Factor A (VEGF-A) and Placental Growth Factor (PlGF).

In patients with wet AMD and myopic CNV, these factors, in excess are involved in the abnormal formation of new blood vessels in the eye. These new blood vessels can cause the leak of blood components into the eye and eventual damage to tissues in the eye responsible for vision

In patients with CRVO, a blockage occurs in the main blood vessel that transports blood away from the retina. VEGF levels are elevated in response causing the leakage of fluid into the retina and thereby causing a swelling of the macula, (the portion of the retina responsible for fine vision), which is called macular oedema. When the macula swells with fluid, central vision becomes blurry.

In patients with BRVO, one or more branches of the main blood vessel that transports blood away from the retina is blocked. VEGF levels are elevated in response causing the leakage of fluid into the retina and thereby causing macular oedema.

Diabetic macular oedema is a swelling of the retina occurring in patients with diabetes due to leaking of fluid from blood vessels within the macula. The macula is the portion of retina responsible for fine vision. When the macula swells with fluid, central vision becomes blurry.

Eylea has been shown to stop the growth of new abnormal blood vessels in the eye which often leak fluid or bleed. Eylea can help to stabilise, and in many cases, improve the vision loss related to wet AMD, CRVO, BRVO, DME and myopic CNV.

【What you need to know before you are given Eylea】

You will not be given Eylea:

- if you are allergic to aflibercept or any of the other ingredients of this medicine.

- if you have an active or suspected infection in or around the eye (ocular or periocular infection).

- if you have severe inflammation of the eye (indicated by pain or redness).

【How you will be given Eylea】

A doctor experienced in giving eye injections will inject Eylea into your eye under aseptic (clean and sterile) conditions.

The recommended dose is 2 mg aflibercept (50 microlitres).

Eylea is given as an injection into your eye (intravitreal injection).

Before the injection your doctor will use a disinfectant eyewash to clean your eye carefully to prevent infection. Your doctor will also give you a local anaesthetic to reduce or prevent any pain you might have with the injection.

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（20193911451811.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------